fda warning letter glp-1 solution september 2025 warns Novo Nordisk over unreported Ozempic and Wegovy side effects Medicare's New GLP-1 Pricing Initiative

Omeprazole was identified as the most cost-effective PPI in this study

In April 2026, The Foundation for Prader-Willi Research (FPWR) announced a venture philanthropy investment in ConSynance Therapeutics to support the advancement of CSTI-500, ConSynance s investigational therapy for the treatment of behavioral dysregulation and hyperphagia in PWS

Adequate water intake can support kidney function and reduce the risk of uric acid kidney stones

It is not part of Medicares Part D drug program, but you must have a Part D plan to be eligible

The marketing environment after April 22 is the most likely near-term enforcement zone